OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-12-31-accounts

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

REGISTERED COMPANY NUMBER: 04133242 (England and Wales) REGISTERED CHARITY NUMBER: 1085527

Report of the Trustees and

Unaudited Financial Statements for the Year Ended 31 December 2023

for

Anaphylaxis UK

Chamberlains Chartered Accountants Elm House, Tanshire Park Shackleford Road, Elstead Godalming Surrey GU8 6LB

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 Anaphylaxis UK

Contents of the Financial Statements for the Year Ended 31 December 2023

Page
Report of the Trustees 1 to 8
Independent Examiner's Report 9
Statement of Financial Activities 10
Balance Sheet 11 to 12
Cash Flow Statement 13
Notes to the Cash Flow Statement 14
Notes to the Financial Statements 15 to 23
Detailed Statement of Financial Activities 24 to 25

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Report of the Trustees

for the Year Ended 31 December 2023

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

The Trustees, who are also the Directors of the Charity for the purposes of the Companies Act, are pleased to present their report, together with the annual financial statements for the year ended 31 December 2023.

2023 - A Year of Remarkable Achievements and Unwavering Performance

Collaborating with Healthcare and Allergy Services

Health-related Research

Page 1

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Report of the Trustees

for the Year Ended 31 December 2023

Patient Information

AllergyWise Training Program

Communications

Social media

Page 2

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Report of the Trustees

for the Year Ended 31 December 2023

Newsletters

AllergyOutlook is our popular monthly newsletter featuring articles and news written to support people with allergies. The newsletter shines a spotlight on the tireless efforts of our charity, keeping subscribers informed about the latest initiatives, groundbreaking services, and the tangible impact we are making in the lives of individuals and families. In the past year alone, our subscriber base has flourished, expanding from 4,600 to 13,000, an astonishing achievement in the period..

Fundraising Highlights

FUNDRAISER FOCUS: #Challenge14 Participants

The participants of the inaugural #Challenge14 fundraising event truly embodied the spirit of determination and compassion, each undertaking a unique challenge to raise awareness of the 14 major food allergens. Among the standout fundraisers were:

FUNDRAISER FOCUS: 10 Years of Celebrating Will

For the past decade, friends and family of Will, who tragically passed away in 2013, have organised an annual charity golf day to raise funds for Anaphylaxis UK. To mark this significant anniversary, the 2023 event was bigger and better than ever, with 34 players and 60 evening guests, raising over £3,000. Over the last 10 years, an extraordinary £15,000 has been generously raised by Will's loved ones, honouring his memory and supporting our mission through their greatly appreciated efforts.

Page 3

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

for the Year Ended 31 December 2023

Report of the Trustees

FUNDRAISER FOCUS: Charity Football Day

In a poignant and heartwarming tribute, friends and family came together in April 2023 to celebrate the memory of James, who tragically passed away from anaphylaxis in February 2018 at the age of 15. On what would have been his 21st birthday, they organised a charity football day, raffle, and auction for Anaphylaxis UK. The event was a resounding success, raising a staggering £5,857 on the day to celebrate James.

Impactful Contributions

The generosity of our supporters has been truly awe-inspiring. Driven by an unwavering dedication to our cause, major donors contributed a remarkable £7,000, providing invaluable support that propelled our ongoing efforts forward. Additionally, we are deeply humbled by the £19,828 raised through heartfelt in memoriam donations, profound tributes that honour the memories of loved ones and underscore the profound impact of our work.

Public donations, totalling an extraordinary £48,305, have been instrumental in fuelling our mission, enabling us to provide vital support services, education and advocacy for individuals and families affected by allergies. These contributions represent more than just financial assistance; they are a testament to the trust and belief our community has placed in us.

Driving Change through Grants

Grants totalling £13,600 have been catalysts for our initiatives, empowering us to keep the allergy community safe and supported. Funding from esteemed Trusts such as The Brian Shaw Memorial Trust, The Ardwick Trust, and The Lady Hind Trust has enabled our information and services team to deliver essential support services to the public, ensuring that no one faces the challenges of allergies alone or without guidance.

Moreover, grants from the CRH Charitable Trust, The Anton Jurgens Charitable Trust, and the Hospital Saturday Fund have paved the way for the development of our pioneering AllergyWise training for Early Years settings. This groundbreaking initiative equips caregivers and educators with the knowledge and tools necessary to create safer environments for children with allergies, fostering inclusivity and protection from a young age.

Anaphylaxis UK Business Symposium

This flagship event, held at the renowned Francis Crick Institute in London in December 2023, was a resounding success. We raised an impressive £26,500 from sponsors of the business symposium, with generous contributions from esteemed partners including RSSL, SGS, ServeLegal, Romer Labs, Neogen, Thermo Fisher Scientific, DBV Technologies, and Christeyns Food Hygiene. This significant support has bolstered our initiatives, enabling us to advance our mission of fostering inclusion and awareness within society.

Additionally, our corporate members' unwavering commitment generated an incredible £75,885 through their memberships. Their partnership has been instrumental in driving positive change and expanding our outreach efforts, amplifying our impact and ensuring our message resonates far and wide.

Through the collective efforts of our dedicated supporters, tireless volunteers, and passionate team members, we have achieved remarkable milestones in 2023. These achievements are not merely statistics or figures; they represent lives transformed, hope rekindled, and a future where individuals with allergies can live with confidence, empowerment, and a profound sense of community.

As we look ahead, we are filled with renewed determination and optimism, fuelled by the successes of the past year and the unwavering commitment. Together, we will continue to forge ahead, advocating for change, raising awareness, and ensuring that no one faces the challenges of allergies alone.

Page 4

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Report of the Trustees for the Year Ended 31 December 2023

Investment performance achieved against investment objectives

The investment objectives of the Charity are to maximise the value of reserves, while avoiding undue risk. The Charity's policy on investment includes a requirement to limit investments to 60% of liquid assets and only to invest in Funds regulated by the Financial Conduct Authority. The Charity's investments in an Income and Growth portfolio with Hargreaves Lansdown showed a gain of £9,471 on the value report at the end of December 2022 (£154,824). The value at the end of December 2023 was £164,295.

Financial review: Reserves policy

To achieve a sound balance between prudence and ensuring funds are expended in achieving the objectives of the Charity, the Trustees have established a policy whereby the unrestricted reserves held by the Charity should equate to at least six months operating costs. At the year end this equated to £245,182. Free reserves (excluding 6 months operating costs) at 31 December 2023 stood at £386,685.

Restricted reserves

There were no restricted reseves at 31 December 2023.

Risk review

The Trustees have conducted a review of the major risks to which the Charity is exposed and systems have been established to manage those risks. A risk management register is maintained and risks highlighted are reviewed regularly to ensure they do not pose a threat to the Charity going forward. Key risks for the Charity include an uncertain economic outlook and its impact on fundraising by individuals and financial support from businesses.

Financial overview

The Charity ended the year in a sound financial position with sufficient free reserves to meet its reserves policy. Net outgoing resources for the year amounted to £579,487. Unrestricted funds were £631,867 and restricted funds were zero.

Financial policies

All payments up to £10,000 made by the Charity have to be signed by two authorised signatories and by a Trustee in addition for payments over that amount. The day-to-day management of the financial affairs of the Charity is delegated to the Head of Finance and Operations who submits Management Accounts and a written report monthly to the CEO and Board of Trustees. A financial report supported by Management Accounts is delivered at each meeting of Trustees.

Principal funding sources

The principal funding sources for the charity are community fundraising initiatives such as the London Marathon, sales from our AllergyWise training programme and from Business Membership. The charity also benefits from grants and sponsorship of project work such as awareness campaigns.

Use of funds

Funds received by the charity have contributed significantly to the expansion of services offered by the Information Team and in our ability to enhance our awareness campaigns to reach more people with allergies.

Page 5

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Report of the Trustees

for the Year Ended 31 December 2023

Plans for the future

The Board have agreed a Strategic Framework for 2023-2028. The general impact the Anaphylaxis UK charity aims to achieve by the end of 2028 is:

We want everyone with a serious allergy to enjoy the same quality of life as someone without an allergy. Over the next five years, all of our work will focus on making this ambition a reality.

Our main priority areas and the impact we aim to achieve within each area are set out in the Business Plan since they were approved by the Board in March 2023. The main areas for future work are:

- Empowering Lives, Conquering Fears in the Years Ahead

For too long, the anxiety of living with an allergy has robbed individuals of the freedom to fully embrace life's cherished moments - from joyous birthday celebrations to simple acts of socialising and exploring the world around them. The ever-present fear of a potential reaction has cast a shadow over the everyday, creating an unacceptable barrier to living life to the fullest. But today, we stand united in our resolve to shatter those barriers and empower our community to reclaim their lives without fear.

Following the success of a groundbreaking Knowledge Transfer (KTP) grant, we are thrilled to announce an unprecedented partnership with the esteemed University of Surrey. Together, we will embark on an ambitious journey, collaborating with renowned clinical psychologists to develop a transformative support system. This pioneering program will equip individuals with the tools and strategies to conquer their anxieties, empowering them with the skills to navigate life's adventures with confidence and resilience.

This visionary initiative marks a milestone in the evolution of our charity, as we expand our horizons to offer life-changing services tailored to the unique needs of our beneficiaries. No longer will fear dictate their choices; instead, they will be equipped with the knowledge and self-assurance to embrace every opportunity, every moment, and every dream.

- Safer Schools, Brighter Futures

Recognising the pivotal role of educational institutions in fostering an inclusive and supportive environment, we will expand our acclaimed AllergyWise portfolio, with a particular emphasis on our Safer Schools Programme. Through this initiative, we will actively encourage more schools to undertake comprehensive training and adopt robust policies and procedures, ensuring that every student with allergies can learn, grow, and thrive in a nurturing and secure environment.

- Forging Powerful Partnerships

In our unwavering pursuit of promoting awareness and understanding, we will enhance our relationships with leading businesses, forging powerful partnerships that amplify our collective impact. Together, we will embark on groundbreaking awareness-raising programs, fostering a culture of inclusion and empathy that transcends boundaries.

- Empowering Businesses, Enriching Lives

Recognising the vital role that small and medium-sized enterprises play in shaping our communities, we will develop an innovative online portal - a comprehensive resource tailored to their unique needs. This dynamic platform will serve as a trusted guide, providing factually accurate support, resources, and insights to help businesses navigate the complexities of allergies with ease. From developing allergy-aware products and services to fostering inclusive practices, we will empower these enterprises to become catalysts for positive change, creating a world where accessibility and understanding are woven into the very fabric of society.

Page 6

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Report of the Trustees for the Year Ended 31 December 2023

- Accessible Information, Trusted Source

Our commitment to providing accurate and trusted information will reach new heights as we embrace diverse mediums to cater to the evolving needs of our beneficiaries. Through captivating infographics, engaging animations, and informative videos, we will ensure that our factsheets and resources are not only informative but also accessible and engaging. By meeting our community where they are, we will solidify our position as the premier trusted source of information, empowering individuals to make informed decisions and navigate their journey with confidence.

Together, we stand at the precipice of a transformative era, where the weight of anxiety is lifted, and the freedom to embrace life's every opportunity is within reach.

Statement of Trustees' responsibilities

The trustees (who are also directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent Examiners

Chamberlains were appointed independent at the Annual General Meeting of the Charity held on 10th June 2024.

STRUCTURE, GOVERNANCE AND MANAGEMENT Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

04133242 (England and Wales)

Page 7

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Report of the Trustees for the Year Ended 31 December 2023

Registered Charity number

1085527

Registered office

1 Alexandra Road Farnborough GU14 6BU

Trustees

Dr A M Walker-Fraser Chair Mr P M Littleton Vice Chair Mr C Meads (resigned 8.6.23) Mrs T Randhawa Mrs L C Wilkinson Mrs S C Hall (resigned 10.4.24) Dr H E Evans-Howells Mr R J Wright KC Mr B Gaventa (resigned 10.3.23) Ms C C A Fearnley (appointed 17.7.23)

Company Secretary

Mrs L A Ingram

Independent Examiner

Paul J Chamberlain FCA DChA Chamberlains Chartered Accountants Elm House, Tanshire Park Shackleford Road, Elstead Godalming Surrey GU8 6LB

12 June 2024 Approved by order of the board of trustees on ............................................. and signed on its behalf by:

[A ........................................................................ 1C4B1FCD180E469...ea by: Dr A M Walker-Fraser - Trustee

Page 8

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Independent Examiner's Report to the Trustees of Anaphylaxis UK

Independent examiner's report to the trustees of Anaphylaxis UK ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2023.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

  1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or

  2. the accounts do not accord with those records; or

  3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or

  4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Paul J Chamberlain FCA DChA The Institute of Chartered Accountants in England and Wales

Chamberlains Chartered Accountants Elm House, Tanshire Park Shackleford Road, Elstead Godalming Surrey GU8 6LB 12 June 2024 Date: .............................................

Page 9

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Statement of Financial Activities for the Year Ended 31 December 2023

Unrestricted
fund
Notes
£
INCOME FROM
Donations and legacies
2
551,512
Charitable activities
5
Sale of educational products
-
Product recall income
-
Other trading activities
3
31,202
Investment income
4
3,383
Total
586,097
EXPENDITURE ON
Raising funds
6
79,256
Charitable activities
7
Charitable activities
496,285
Other
3,946
Total
579,487
Net gains/(losses) on investments
9,471
NET INCOME
16,081
RECONCILIATION OF FUNDS
Total funds brought forward
613,648
TOTAL FUNDS CARRIED FORWARD
629,729		 Restricted
funds
£
-
-
-
-
-
-
-
-
-
-
-
-
-
-		 31.12.23
31.12.22
Total
Total
funds
funds
£
£
551,512
354,712
-
68,116
-
42,902
31,202
73,134
3,383
2,030
586,097
540,894
79,256
76,821
496,285
421,369
3,946
31,347
579,487
529,537
9,471
(8,078)
16,081
3,279
613,648
610,369
629,729
613,648

The notes form part of these financial statements

Page 10

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Balance Sheet

31 December 2023

Unrestricted
fund
Notes
£
FIXED ASSETS
Intangible assets
13
37,963
Tangible assets
14
10,933
Investments
15
164,296
213,192
CURRENT ASSETS
Stocks
16
311
Debtors
17
150,045
Cash in hand
322,519
472,875
CREDITORS
Amounts falling due within one year
18
(56,338)
NET CURRENT ASSETS
416,537
TOTAL ASSETS LESS CURRENT
LIABILITIES
629,729
NET ASSETS
629,729
FUNDS
19
Unrestricted funds
TOTAL FUNDS		 Restricted
funds
£
-
-
-
-
-
-
-
-
-
-
-
-		 31.12.23
Total
funds
£
37,963
10,933
164,296
213,192
311
150,045
322,519
472,875
(56,338)
416,537
629,729
629,729
629,729
629,729		 31.12.22
Total
funds
£
43,183
15,035
154,824
213,042
828
70,689
373,041
444,558
(43,952)
400,606
613,648
613,648
613,648
613,648

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

The notes form part of these financial statements

continued...

Page 11

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Balance Sheet - continued 31 December 2023

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 12 June 2024 ............................................. and were signed on its behalf by:

............................................. [A1C4B1FCD180E469...ea by: Dr A M Walker-Fraser - Trustee

The notes form part of these financial statements

Page 12

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Cash Flow Statement for the Year Ended 31 December 2023

Notes
Cash flows from operating activities
Cash generated from operations
1
Net cash (used in)/provided by operating activities
Cash flows from investing activities
Purchase of intangible fixed assets
Purchase of tangible fixed assets
Purchase of fixed asset investments
Sale of intangible fixed assets
Sale of tangible fixed assets
Interest received
Net cash used in investing activities
Change in cash and cash equivalents in
the reporting period
Cash and cash equivalents at the
beginning of the reporting period
Cash and cash equivalents at the end of
the reporting period		 31.12.23
£
(37,824)
(37,824)
(12,632)
(3,448)
(1)
2,950
(2,950)
3,383
(12,698)
(50,522)
373,041
322,519		 31.12.22
£
19,714
19,714
(45,670)
(8,909)
-
-
5,265
2,030
(47,284)
(27,570)
400,611
373,041

The notes form part of these financial statements

Page 13

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Notes to the Cash Flow Statement for the Year Ended 31 December 2023

1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

31.12.23 31.12.22
£ £
Net income for the reporting period (as per the Statement of Financial
Activities) 16,081 3,279
Adjustments for:
Depreciation charges 21,456 15,710
(Gain)/losses on investments (9,471) 8,078
Loss on disposal of fixed assets 3,946 -
Interest received (3,383) (2,030)
Decrease in stocks 517 2,379
Increase in debtors (79,357) (13,551)
Increase in creditors 12,387 5,849
Net cash (used in)/provided by operations (37,824) 19,714

2. ANALYSIS OF CHANGES IN NET FUNDS

Net cash At 1.1.23
£		 Cash flow
£		 At 31.12.23
£		 At 31.12.23
£
Cash at bank and in hand 373,041 (50,522) 322,519
373,041 (50,522) 322,519
Total 373,041 (50,522) 322,519

The notes form part of these financial statements

Page 14

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442 Anaphylaxis UK

Notes to the Financial Statements

for the Year Ended 31 December 2023

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

Preparation of consolidated financial statements

The financial statements contain information about Anaphylaxis UK as an individual company and do not contain consolidated financial information as the parent of a group. The charity is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Anaphylaxis UK has one subsidiary, Anaphylaxis UK Trading Ltd. The registered office of the subsidiary is 1 Alexandra Road, Farnborough, GU14 6BU. Anaphylaxis UK owns 100% of the £1 ordinary share capital of the subsidiary.

The subsidiary company carries out trading activities related to the objectives of Anaphylaxis UK. All the taxable profits of the subsidiary are paid by gift to Anaphylaxis UK and are used in the furtherance of the charity's objectives. Consequently, the total reserves of the subsidiary are its £1 ordinary share capital.

Total income and expenditure of the subsidiary in the year to 31 December 2023 were £264,800, including ££200,940 paid by gift to Anaphylaxis UK.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

continued...

Page 15

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Notes to the Financial Statements - continued for the Year Ended 31 December 2023

1. ACCOUNTING POLICIES - continued

Fund accounting

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease.

Investments

Fixed asset investments are treated as a single asset, revalued each year to current market value.

2. DONATIONS AND LEGACIES

Donations - members
Memoriam donations
Gift aid
Community fundraising & events
Charitable trusts and major donors
Corporate donations
Legacies
Individual membership
Professional membership
Corporate membership
Other including Google Adwords
Income from subsidiary		 31.12.23
£
27,638
19,828
27,636
46,233
20,600
7,135
501
43,876
2,443
-
96,733
258,889
551,512		 31.12.22
£
29,595
30,151
37,906
23,386
38,600
8,825
13,986
47,433
3,096
57,955
63,779
-
354,712

Since 1 January 2023 a number of activities previously undertaken by Anaphylaxis UK have been carried out by its subsidiary, Anaphylaxis UK Trading Ltd. These include corporate membership, Allergywise training, product recall work, events, special projects and some other activities. All of Anaphylaxis UK Trading Ltd's surplus for the year is gifted to Anaphylaxis UK and is included in Donations and Legacies.

3. OTHER TRADING ACTIVITIES

OTHER TRADING ACTIVITIES
Shop income 31.12.23
31.12.22
£
£
-
909
Event income 15,322
16,441
Special project income 12,380
43,700
Other sundry income -
8,784
Corporate sponsorship 3,500
3,300
31,202
73,134

continued...

Page 16

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Notes to the Financial Statements - continued for the Year Ended 31 December 2023

4. INVESTMENT INCOME

INVESTMENT INCOME
31.12.23 31.12.22
£ £
Dividends and interest rec'd 3,383 2,030

5. INCOME FROM CHARITABLE ACTIVITIES

The split of income from charitable activities is shown in the Statement of Financial Activities.

6. RAISING FUNDS

Raising donations and legacies

Staff costs
Other fundraising costs
Support costs
7.
CHARITABLE ACTIVITIES COSTS
Charitable activities
8.
SUPPORT COSTS
Raising donations and legacies
Charitable activities
9.
NET INCOME/(EXPENDITURE)
Net income/(expenditure) is stated after charging/(crediting):
Audit fee
Auditor's remuneration for other work
Depreciation - owned assets
Hire of plant and machinery
Other operating leases
Deficit on disposal of fixed assets
Computer software amortisation		 31.12.23
£
26,269
10,650
42,337
79,256
Support
Direct
costs (see
Costs
note 8)
£
£
305,376
190,909
General
Governance
costs
costs
£
£
42,337
-
157,586
33,323
199,923
33,323
31.12.23
£
-
-
6,554
7,705
45,246
3,946
14,902		 31.12.22
£
24,224
9,457
43,140
76,821
Totals
£
496,285
Totals
£
42,337
190,909
233,246
31.12.22
£
5,150
750
5,880
8,775
34,723
-
9,830

continued...

Page 17

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Notes to the Financial Statements - continued for the Year Ended 31 December 2023

10. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2023 nor for the year ended 31 December 2022.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 December 2023 nor for the year ended 31 December 2022.

11. STAFF COSTS

Wages and salaries
The average monthly number of employees during the year was as follows:
Fundraising
Charitable activities		 31.12.23
£
305,647
305,647
31.12.23
1
7
8		 31.12.22
£
286,898
286,898
31.12.22
1
7
8

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

£60,001 - £70,000 31.12.23
-		 31.12.22
1
£70,001 - £80,000 1 -
1 1
12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES
INCOME FROM Unrestricted
fund
£		 Restricted
funds
£		 Total
funds
£
Donations and legacies 354,712 - 354,712
Charitable activities
Sale of educational products 68,116 - 68,116
Product recall income 42,902 - 42,902
Other trading activities 73,134 - 73,134
Investment income 2,030 - 2,030
Total 540,894 - 540,894
EXPENDITURE ON
Raising funds 76,821 - 76,821
Charitable activities
Charitable activities 418,226 3,143 421,369

continued...

Page 18

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Notes to the Financial Statements - continued for the Year Ended 31 December 2023

12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued
Unrestricted Restricted Total
fund funds funds
£ £ £
Other 31,347 - 31,347
Total 526,394 3,143 529,537
Net gains/(losses) on investments (8,078) - (8,078)
NET INCOME/(EXPENDITURE) 6,422 (3,143) 3,279
RECONCILIATION OF FUNDS
Total funds brought forward 607,226 3,143 610,369
TOTAL FUNDS CARRIED FORWARD 613,648 - 613,648
13. INTANGIBLE FIXED ASSETS
COST Computer
software
£
At 1 January 2023 58,911
Additions 12,632
Disposals (13,241)
At 31 December 2023 58,302
AMORTISATION
At 1 January 2023 15,728
Charge for year 14,902
Eliminated on disposal (10,291)
At 31 December 2023 20,339
NET BOOK VALUE
At 31 December 2023 37,963
At 31 December 2022 43,183

continued...

Page 19

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Notes to the Financial Statements - continued for the Year Ended 31 December 2023

14. TANGIBLE FIXED ASSETS

TANGIBLE FIXED ASSETS
Plant and
machinery
£
COST
At 1 January 2023 37,850
Additions 3,448
Disposals (15,409)
At 31 December 2023 25,889
DEPRECIATION
At 1 January 2023 22,815
Charge for year 6,554
Eliminated on disposal (14,413)
At 31 December 2023 14,956
NET BOOK VALUE
At 31 December 2023 10,933
At 31 December 2022 15,035

15. FIXED ASSET INVESTMENTS

Shares in
group
Listed
undertakings
investments
£
£
MARKET VALUE
At 1 January 2023
-
154,824
Additions
1
-
Revaluations
-
9,471
At 31 December 2023
1
164,295
NET BOOK VALUE
At 31 December 2023
1
164,295
At 31 December 2022
-
154,824		 Totals
£
154,824
1
9,471
164,296
164,296
154,824

There were no investment assets outside the UK.

Anaphylaxis UK holds the entire £1 share capital of its trading subsidiary Anaphylaxis UK Trading Ltd. The subsidiary began trading on 1 January 2023 and its income for the year to 31 December 2023 was £289,629. The subsidiary gifts its taxable profit to Anaphylaxis UK and consequently it had no reserves at 31 December 2023 other than its share capital of £1.

Listed fixed asset investments are revalued each year by the external fund managers.

continued...

Page 20

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Notes to the Financial Statements - continued for the Year Ended 31 December 2023

16.
STOCKS
Finished goods
17.
DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
Trade debtors
Amounts owed by group undertakings
VAT
Prepayments and accrued income
Accrued income
18.
CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
Trade creditors
Social security and other taxes
Accruals and deferred income
Accrued expenses
19.
MOVEMENT IN FUNDS
At 1.1.23
£
Unrestricted funds
General fund
613,648
TOTAL FUNDS
613,648
Net movement in funds, included in the above are as follows:
Incoming
Resources
resources
expended
£
£
Unrestricted funds
General fund
586,097
(579,487)
TOTAL FUNDS
586,097
(579,487)		 31.12.23
31.12.22
£
£
311
828
31.12.23
31.12.22
£
£
3,784
23,449
85,643
-
5,105
2,190
45,801
36,903
9,712
8,147
150,045
70,689
31.12.23
31.12.22
£
£
39,960
29,564
6,625
5,078
1,948
2,469
7,805
6,841
56,338
43,952
Net
movement
At
in funds
31.12.23
£
£
16,081
629,729
16,081
629,729
Gains and
Movement
losses
in funds
£
£
9,471
16,081
9,471
16,081

continued...

Page 21

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Notes to the Financial Statements - continued for the Year Ended 31 December 2023

19. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

At 1.1.22
£
Unrestricted funds
General fund
607,226
Restricted funds
Isle of Man Fund
3,143
TOTAL FUNDS
610,369
Comparative net movement in funds, included in the above are as follows:
Incoming
Resources
resources
expended
£
£
Unrestricted funds
General fund
540,894
(526,394)
Restricted funds
Isle of Man Fund
-
(3,143)
TOTAL FUNDS
540,894
(529,537)
A current year 12 months and prior year 12 months combined position is as follows:
At 1.1.22
£
Unrestricted funds
General fund
607,226
Restricted funds
Isle of Man Fund
3,143
TOTAL FUNDS
610,369		 Net
movement
At
in funds
31.12.22
£
£
6,422
613,648
(3,143)
-
3,279
613,648
Gains and
Movement
losses
in funds
£
£
(8,078)
6,422
-
(3,143)
(8,078)
3,279

Net
movement
At
in funds
31.12.23
£
£
22,503
629,729
(3,143)
-
19,360
629,729

continued...

Page 22

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Notes to the Financial Statements - continued

for the Year Ended 31 December 2023

19. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

Incoming
Resources
resources
expended
£
£
Unrestricted funds
General fund
1,126,991
(1,105,881)
Restricted funds
Isle of Man Fund
-
(3,143)
TOTAL FUNDS
1,126,991
(1,109,024)		 Gains and
Movement
losses
in funds
£
£
1,393
22,503
-
(3,143)
1,393
19,360

20. RELATED PARTY DISCLOSURES

In October 2022 a subsidiary company, Anaphylaxis UK Trading Ltd, was formed. This subsidiary commenced trading in 2023. In the year to 31 December 2023 the subsidiary had income of £289,629. In accordance with the agreement between the two entities, the whole of Anaphylaxis UK Trading Ltd's taxable profit of £200,940 was paid to Anaphylaxis UK.

Page 23

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Detailed Statement of Financial Activities for the Year Ended 31 December 2023

Detailed Statement of Financial Activities
for the Year Ended 31 December 2023
31.12.23 31.12.22
£ £
INCOME
Donations and legacies
Donations - members 27,638 29,595
Memoriam donations 19,828 30,151
Gift aid 27,636 37,906
Community fundraising & events 46,233 23,386
Charitable trusts and major donors 20,600 38,600
Corporate donations 7,135 8,825
Legacies 501 13,986
Individual membership 43,876 47,433
Professional membership 2,443 3,096
Corporate membership - 57,955
Other including Google Adwords 96,733 63,779
Income from subsidiary 258,889 -
Other trading activities 551,512 354,712
Shop income - 909
Event income 15,322 16,441
Special project income 12,380 43,700
Other sundry income - 8,784
Corporate sponsorship 3,500 3,300
Investment income 31,202 73,134
Dividends and interest rec'd 3,383 2,030
Charitable activities
Sale of educational products - 68,116
Product recall income - 42,902
- 111,018
Total incoming resources 586,097 540,894
EXPENDITURE
Raising donations and legacies
Wages 26,269 24,224
Other fundraising costs 10,650 9,457
36,919 33,681
Charitable activities
Wages 184,957 188,163
Shop and activity purchases 92,745 84,629
Carried forward 277,702 272,792

This page does not form part of the statutory financial statements

Page 24

DocuSign Envelope ID: 168DB30F-729C-4351-B59E-B650970BD442

Anaphylaxis UK

Detailed Statement of Financial Activities
for the Year Ended 31 December 2023
31.12.23 31.12.22
£ £
Charitable activities
Brought forward 277,702 272,792
Contractor costs 19,695 23,800
Conference and events 1,636 694
Special projects 6,343 5,607
Other 305,376 302,893
Loss on sale of tangible fixed assets 3,946 -
Support costs
General costs
Wages 67,598 49,397
Rent and rates 7,705 8,775
Computer and software costs 45,246 34,723
Telephone 5,983 5,412
Travel and subsistence 2,150 2,072
Recruitment and redundancy 421 757
Staff training 2,034 2,074
Office expenses 1,091 2,625
Stationery and printing 620 102
Postage and carriage 246 2,160
Professional fees 2,119 4,678
Website costs 1,524 3,189
Insurance 2,018 2,350
Irrecoverable VAT 22,745 15,447
Sundry 10,627 6,904
Bank charges 6,340 5,241
Plant and machinery 21,456 15,710
Governance costs 199,923 161,616
Wages 26,823 25,114
Auditors' remuneration - 5,900
Sundries - 333
Accountancy and legal fees 6,500 -
33,323 31,347
Total resources expended 579,487 529,537
Net income 6,610 11,357

This page does not form part of the statutory financial statements

Page 25